Biotech Valuation Idiosyncrasies and Best Practices
Biotech companies with little to no revenue can still be worth billions. Consider the most prominent 2017 biotech M&A deal when Gilead bought Kite Pharma for almost $12 billion. At the time of the deal, Kite had over $600 million in accumulated deficit, but it also had a pipeline of CAR-T cell therapies, which treat cancer. This article examines how to value such pipelines. It also focuses on the risk-adjusted NPV valuation methodology, portfolios of multiple drug candidates, and how value is impacted by the characteristics of the investor or acquirer.
This site explains how a Company with no Revenue can be worth Billions , especially those with Positive Data and goes on the explain how a Valuation increases upon FDA Application / Approval
https://www.toptal.com/finance/valuation/biotech-valuation
- Forums
- ASX - By Stock
- PAA
- Ann: Appendix 4C and Quarterly Update
Ann: Appendix 4C and Quarterly Update, page-30
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
22.5¢ |
Change
0.005(2.27%) |
Mkt cap ! $100.1M |
Open | High | Low | Value | Volume |
22.0¢ | 22.5¢ | 21.5¢ | $194.1K | 889.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 4996 | 22.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.5¢ | 114999 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4996 | 0.220 |
4 | 111400 | 0.215 |
6 | 149372 | 0.210 |
4 | 321081 | 0.205 |
12 | 441445 | 0.200 |
Price($) | Vol. | No. |
---|---|---|
0.225 | 114999 | 4 |
0.230 | 191213 | 6 |
0.240 | 134752 | 2 |
0.245 | 71127 | 2 |
0.250 | 93723 | 5 |
Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |